Related Experiment Video
Updated: Oct 22, 2025
09:20
Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction
Published on: February 13, 2021
6.7K
Association Between Arterial Stiffness and Heart Failure With Preserved Ejection Fraction
Chen Chi1, Yifan Liu1, Yawei Xu1
1Department of Cardiology, Shanghai Tenth People's Hospital, Tongji University School of Medicine, Shanghai, China.
Frontiers in Cardiovascular Medicine
|August 30, 2021
Summary
Arterial stiffness may contribute to heart failure with preserved ejection fraction (HFpEF), a major cause of cardiovascular mortality. Further research into effective treatments for arterial stiffness and HFpEF is urgently needed.
Area of Science:
- Cardiology
- Vascular Medicine
Background:
- Cardiovascular diseases are the leading global cause of death.
- Heart failure with preserved ejection fraction (HFpEF) constitutes approximately 50% of all heart failure cases.
- The underlying mechanisms of HFpEF remain poorly understood, hindering effective treatment development.
Purpose of the Study:
- To explore the relationship between arterial stiffness and HFpEF.
- To elucidate the contribution of arterial stiffness to the development of HFpEF.
- To review current therapeutic strategies for arterial stiffness and HFpEF.
Main Methods:
- Literature review and synthesis of existing research.
- Discussion of the pathophysiological links between arterial stiffness and diastolic dysfunction.
- Analysis of current treatment options and their limitations.
Main Results:
- Arterial stiffness, characterized by reduced arterial compliance, is an independent risk factor for cardiovascular disorders, including diastolic dysfunction.
- Evidence suggests a significant association between arterial stiffness and the pathophysiology of HFpEF.
- Current pharmacologic treatments for arterial stiffness and HFpEF show limited efficacy and require further safety and effectiveness evaluation.
Conclusions:
- Arterial stiffness is a potential contributor to HFpEF.
- Novel pharmacological treatments targeting arterial stiffness are essential for improving HFpEF outcomes.
- Urgent development and rigorous assessment of new therapies are needed for both arterial stiffness and HFpEF.
Related Concept Videos
01:17Pathophysiology of Heart Failure
2.0K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
2.0K
01:29Heart Failure II: Pathophysiology
108
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
108
01:27Heart Failure I: Introduction
159
Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
159
01:30Heart Failure IV: Classification and Diagnostic Evaluation
74
Heart failure can be classified in various ways, with the most common classifications based on physical activity limitations, disease progression, severity, and treatment strategies.The Functional Classification of Heart Failure divides patients into four categories based on physical activity limitation due to symptom burden.Class I: Patients in this class have cardiac disease but no physical activity limitations. Ordinary activities like walking, climbing stairs, or routine tasks do not cause...
74
01:23Rheumatic Heart Disease I: Introduction
118
Rheumatic heart disease or RHD is a chronic condition that results from rheumatic fever, causing permanent damage to the heart valves.Etiology and Risk FactorsIt primarily arises from rheumatic fever, an inflammatory disease that can develop after untreated or inadequately treated group A streptococcal (GAS) pharyngitis. Streptococcus spreads through direct contact with oral or respiratory secretions. While the bacteria are the causative agents, factors like malnutrition, overcrowding, poor...
118
01:22Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies
133
The key clinical manifestations of Rheumatic heart disease (RHD) include several distinct cardiac symptoms.Carditis, a hallmark of acute rheumatic fever, involves inflammation of the heart's endocardium, myocardium, and pericardium. Chronic RHD often results from recurrent episodes of carditis. Its symptoms include the following:Murmurs are caused by valvular damage, especially to the mitral and aortic valves. Mitral stenosis or regurgitation is common, with characteristic heart murmurs...
133